2ml x 10 ampoules
5ml x 5 ampoules
Cerebrinel contains low-molecular-weight biologically active neuropeptides that penetrate the blood-brain barrier and directly reach nerve cells. It has an organ-specific, multimodal effect on the brain, providing metabolic regulation, neuroprotection, functional neuromodulation, and neurotrophic activity.
Metabolic regulation: Cerebrinel increases the efficiency of aerobic energy metabolism in the brain and improves intracellular protein synthesis in the developing and aging brain.
Neuroprotection: Cerebrinel protects neurons from the damaging effects of lactic acidosis, prevents the formation of free radicals, increases survival and prevents neuronal death under conditions of hypoxia and ischemia, and reduces the damaging neurotoxic effects of excitatory amino acids (glutamate).
Neurotrophic activity: Cerebrinel is a nootropic peptidergic drug with proven neurotrophic activity similar to that of natural neuronal growth factors (NGF), but manifested through peripheral administration.
Functional neuromodulation: Cerebrinel has a positive effect on cognitive impairment and memory processes.
Indications
- Alzheimer's disease;
- Cognitive impairment syndrome of various origins, including dementia;
- Chronic cerebrovascular insufficiency (chronic cerebral ischemia, cerebrovascular insufficiency);
- Ischemic stroke;
- Traumatic brain injury;
- Mental retardation in children;
- Attention deficit hyperactivity disorder (ADHD) in children;
- As part of combination therapy for endogenous depression resistant to antidepressants.
Active ingredient: 215.2 mg of porcine brain-derived peptide complex
Administered parenterally. Dosage and duration of treatment depend on the nature and severity of the disease, as well as the patient's age. Single doses of up to 50 ml may be administered, but a course of treatment is preferred.
The recommended optimal course of treatment is daily injections for 10-20 days.
Alzheimer's disease 10-30 ml
Cognitive impairment syndrome of various origins, including dementia 5-30 ml
Chronic cerebrovascular insufficiency (chronic cerebral ischemia, cerebrovascular insufficiency) 5-20 ml
Ischemic stroke:
- acute period
- recovery period
10-50 ml
5-30 ml
Traumatic brain injury 5-50 ml
Mental retardation in children 0.1-0.2 ml/kg body weight
Attention deficit hyperactivity disorder in children 0.1-0.2 ml/kg body weight
As part of combination therapy for endogenous depression resistant to antidepressants 5-30 ml
To enhance treatment effectiveness, repeat courses may be administered until improvement in the patient's condition is observed. After the first course, the frequency of administration can be reduced to 2 or 3 times per week.
Cerebrinel is administered by injection: intramuscularly (up to 5 ml) and intravenously (up to 10 ml). Doses between 10 ml and 50 ml are recommended to be administered only by slow intravenous infusion after dilution with the recommended standard infusion solutions. Infusion duration ranges from 15 to 60 minutes.
